首页> 外文期刊>Therapeutic Drug Monitoring >Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation.
【24h】

Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation.

机译:麦考酚酸在成人移植后的药代动力学和浓度控制研究。

获取原文
获取原文并翻译 | 示例
       

摘要

Data have emerged that provide the scientific basis for therapeutic drug monitoring of mycophenolic acid (MPA) in transplant patients receiving mycophenolate mofetil (MMF), the parent drug, in combination with other immunosuppressive agents. There is a significant relationship between the dose-interval MPA AUC and risk for acute rejection based on retrospective investigations in renal and heart transplant patients and on prospective investigations in renal transplant patients. The MPA dose-interval AUC varies naturally by more than 10-fold in renal and heart transplant patients. Other significant sources of pharmacokinetic variability for MPA include the effects of concomitant medications, and the effects of disease states such as renal dysfunction and liver disease on the steady state MPA AUC. Individualized MMF dose evaluation, guided by MPA plasma concentrations, is becoming the standard of practice at a growing number of transplant centers worldwide because of these factors and because of the need to closely evaluate the immunosuppression afforded by MPA when a change in the immunosuppression regimen in stable transplant patients is planned. Investigations of therapeutic drug monitoring strategies with an emphasis on identifying an optimal abbreviated sampling strategy for MPA AUC estimation are ongoing. Based on the concentration-outcome studies and experience at the authors' institutions and other centers, the authors propose a set of therapeutic drug monitoring guidelines for MPA in stable renal and heart transplant patients for the immediate (first 3 months posttransplant) and maintenance (>3 months) periods. When MPA binding to human serum albumin is altered, as occurs in patients with significant renal dysfunction, liver disease, or a substantial reduction in human serum albumin concentration, the possibility of increased MPA free fraction and free concentration will need to be taken into account in the interpretation of MPA total concentrations.
机译:已经出现了数据,为接受母体药物麦考酚酸酯(MMF)和其他免疫抑制剂联合治疗的移植患者中的麦考酚酸(MPA)的治疗药物监测提供了科学依据。根据肾脏和心脏移植患者的回顾性研究以及肾脏移植患者的前瞻性研究,剂量间隔MPA AUC与急性排斥风险之间存在显着的关系。在肾脏和心脏移植患者中,MPA剂量间隔的AUC自然变化超过10倍。 MPA药动学变异性的其他重要来源包括同时用药的影响,以及疾病状态(如肾功能不全和肝脏疾病)对稳态MPA AUC的影响。由于这些因素,并且由于在免疫抑制方案改变时需要密切评估MPA提供的免疫抑制作用,在全世界越来越多的移植中心,以MPA血浆浓度为指导的个体化MMF剂量评估已成为实践标准。已计划有稳定的移植患者。目前正在进行有关治疗药物监测策略的研究,重点是确定MPA AUC估算的最佳缩写抽样策略。根据作者机构和其他中心的集中结果研究和经验,作者提出了一套稳定的肾脏和心脏移植患者在即刻(移植后的前三个月)和维持治疗中MPA的治疗药物监测指南。 3个月)。当MPA与人血清白蛋白的结合发生改变时,如发生在严重肾功能不全,肝病或人血清白蛋白浓度大幅下降的患者中,则需要考虑MPA游离分数和游离浓度升高的可能性。 MPA总浓度的解释。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号